Logo

Intrexon Goes Public, Shares Steeply Up on First Day of Trading

Aug 09, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Intrexon's shares were up as much as 69 percent on its first day of trading on the New York Stock Exchange today.

In afternoon trading, shares of the Germantown, Md.-based synthetic biology firm remained sharply up at 50 percent at $24.05.

It had priced its initial public offering of nearly 10 million shares at $16 per share, the upper end of an earlier anticipated price range. Intrexon also has granted underwriters a 30-day option to buy up to about 1.5 million additional shares of the company's stock. JP Morgan and Barclays are the joint book-running agents on the offering.

Intrexon's shares trade under ticker symbol "XON". The company filed to go public in early July.

Filed under

Tools & Technology
Business News
Synthetic Biology
IPO
Intrexon
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.